Standard of Care IST — Competitive Intelligence Brief

Standard of Care IST (Standard of Care IST) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P receptor modulator. Area: Neurology.

phase 3 S1P receptor modulator S1P1, S1P3, S1P4, S1P5, S1P6 Neurology Small molecule

Target snapshot

Standard of Care IST (Standard of Care IST) — Biogen. IST is a disease-modifying therapy that targets the immune system to slow disease progression in multiple sclerosis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard of Care IST TARGET	Standard of Care IST	Biogen	phase 3	S1P receptor modulator	S1P1, S1P3, S1P4, S1P5, S1P6
Group S+T	Group S+T	Huazhong University of Science and Technology	marketed	S1P receptor modulator	S1P1
Elizaria®	Elizaria®	AO GENERIUM	phase 3	S1P receptor modulator	S1P1
Aplause®	Aplause®	Phytopharm Consulting Brazil	phase 3	S1P receptor modulator	S1PR1
allo-APZ2-OTS	allo-APZ2-OTS	RHEACELL GmbH & Co. KG	phase 3	S1P receptor modulator	S1PR1
GP404141	GP404141	Geropharm	phase 3	S1P receptor modulator	S1P receptor
Fp MDPI	Fp MDPI	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	S1P receptor modulator	S1PR1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P receptor modulator class)

1. Promius Pharma, LLC · 2 drugs in this class
2. Nobelpharma · 2 drugs in this class
3. Bausch & Lomb Incorporated · 1 drug in this class
4. Biogen · 1 drug in this class
5. Celgene · 1 drug in this class
6. Geropharm · 1 drug in this class
7. GlaxoSmithKline · 1 drug in this class
8. Hoffmann-La Roche · 1 drug in this class
9. Huazhong University of Science and Technology · 1 drug in this class
10. Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class